Since China Biologic Products Holdings Inc. (NASDAQ:CBPO) and Editas Medicine Inc. (NASDAQ:EDIT) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of both companies.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|China Biologic Products Holdings Inc.||94||7.74||N/A||3.36||28.57|
|Editas Medicine Inc.||24||52.55||N/A||-2.27||0.00|
Table 1 highlights China Biologic Products Holdings Inc. and Editas Medicine Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 demonstrates the return on equity, net margins and return on assets of China Biologic Products Holdings Inc. and Editas Medicine Inc.
|Net Margins||Return on Equity||Return on Assets|
|China Biologic Products Holdings Inc.||0.00%||0%||0%|
|Editas Medicine Inc.||0.00%||-47.6%||-27.4%|
Risk and Volatility
China Biologic Products Holdings Inc.’s volatility measures that it’s 26.00% more volatile than Standard & Poor’s 500 due to its 1.26 beta. From a competition point of view, Editas Medicine Inc. has a 2.51 beta which is 151.00% more volatile compared to Standard & Poor’s 500.
The Current Ratio of China Biologic Products Holdings Inc. is 12.6 while its Quick Ratio stands at 10.3. The Current Ratio of rival Editas Medicine Inc. is 8.5 and its Quick Ratio is has 8.5. China Biologic Products Holdings Inc. is better equipped to clear short and long-term obligations than Editas Medicine Inc.
Insider & Institutional Ownership
China Biologic Products Holdings Inc. and Editas Medicine Inc. has shares held by institutional investors as follows: 46.5% and 78.9%. Insiders held 44.13% of China Biologic Products Holdings Inc. shares. Comparatively, Editas Medicine Inc. has 3.98% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|China Biologic Products Holdings Inc.||1.14%||0.63%||-4.24%||22.63%||-5.58%||26.37%|
|Editas Medicine Inc.||-2.88%||4.17%||8.74%||18.66%||-14.14%||10.99%|
For the past year China Biologic Products Holdings Inc.’s stock price has bigger growth than Editas Medicine Inc.
On 7 of the 8 factors China Biologic Products Holdings Inc. beats Editas Medicine Inc.
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.